OSR Health

OSRH

Market cap $14.4M

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program. The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma. Prof. Wolfgang Wick, M.D.

BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication with the Company that the Company's Shareholder Loyalty Contingent Value Rights (CVR) program will not result in any mechanical adjustment to the price of OSR Health's common stock - either upon the distribution of the CVRs or upon the delivery of additional shares of common stock to enrolled holders under the program. What this means for shareholders: No mechanical price adjustment.

BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders. To Every OSR Health Shareholder: OSR Health is at an inflection point - one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market.

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split.

Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026.

BELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly reflects the Company's mission. The change became effective on June 11, 2026 upon the filing of a Certificate of Amendment with the Delaware Secretary of State.

BELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders, As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead: Strategic Focus and Business Development Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.

Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million. The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe AG ("BCME") for VXM01, which includes up to $815 million in milestone payments tied to the development and commercialization of the program.

A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.